Charles River Laboratories International (NYSE:CRL) Price Target Raised to $140.00

Charles River Laboratories International (NYSE:CRL) had its price target boosted by Robert W. Baird from $118.00 to $140.00 in a report issued on Thursday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

CRL has been the topic of a number of other research reports. Evercore ISI raised shares of Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 target price on the stock in a research note on Thursday. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. UBS Group restated a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Mizuho decreased their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a report on Wednesday, April 9th. Finally, William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $176.00.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $138.84 on Thursday. The business’s 50 day moving average is $138.40 and its two-hundred day moving average is $166.32. The company has a market cap of $6.82 billion, a P/E ratio of 925.60, a P/E/G ratio of 4.54 and a beta of 1.50. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period last year, the business posted $2.27 EPS. The business’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rothschild Investment LLC raised its holdings in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 144 shares during the last quarter. HM Payson & Co. bought a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $31,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the fourth quarter worth $37,000. Finally, GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after acquiring an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).